Results 221 to 230 of about 198,722 (342)

Identification of novel FGFR2::TXLNB Fusion in a polymorphous low‐grade neuroepithelial tumor of the young

Brain Pathology, EarlyView.
We report a novel FGFR2::TXLNB fusion in a child with hippocampal PLNTY. This fusion likely drives tumorigenesis via homodimerization and activation of MAPK/PI3K pathways, expanding PLNTY's molecular spectrum and suggesting a potential therapeutic target.
Sha‐Sha Hu, Tian‐Yuan Tan, Wei Yan, Bo Wang   +3 more
wiley   +1 more source

BRAF mutation and tumor immune microenvironment in new era. [PDF]

Am J Cancer Res
Zhou J, Li C, Zhang L, Si Y, Zhang X, Shen M.   +5 more
europepmc   +1 more source

Malignant craniopharyngiomas: Institutional experience and literature review

Brain Pathology, EarlyView.
We report the second case of malignant craniopharyngioma with BAP1 and TP53 mutations. A literature review identified 44 cases of malignant craniopharyngiomas with a median overall survival of 6 months. Eighteen (41%) occurred in patients without any history of radiation, suggesting that mechanisms other than radiation have contributed to their ...
Thomas J. Auen, Isabella W. Zhang, Weiwei Zhang, Jordan M. Burr, Matthew L. Carda, James L. Wisecarver, Nicole Shonka, Jesse L. Cox, Sahara J. Cathcart, Allison Cushman‐Vokoun, Jie Chen   +10 more
wiley   +1 more source

BRAF^V595E detection, uroplakin II expression and PAS staining for diagnosing canine urothelial carcinoma. [PDF]

Vet Res Commun
Kitnitchee M, Sirivisoot S, Siripoonsub J, Chimnakboon N, Punyathi P, Techangamsuwan S, Rungsipipat A.   +6 more
europepmc   +1 more source

BRAF Inhibitors and Control of Mutant BRAF Effects

Cancer Therapy & Oncology International Journal, 2023
openaire   +1 more source

BRAF ^<b>V600E</b> Metastatic Synovial Sarcoma Treated with BRAF & MEK Inhibitors Achieves Complete Response. A Case Report & Literature Review. [PDF]

Oncol Res
Burg D, Babkoff A, Or O, Olshinka N, Demma JA, Adila M, Wygoda M, Blumenfeld P, Diment J, Galiner M, Azraq Y, Katz D, Reissman P, Ostrowicki S, Sebbag G, Elkhateeb N, Moshe AH, Jaber D, Hollander A, Rubin L, Zick A.   +20 more
europepmc   +1 more source

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status. [PDF]

Front Oncol
Brose MS, Keam B, Krajewska J, Hoff AO, Vaisman F, Lin CC, Hitre E, Bowles DW, Robinson B, Sherman SI, Ngamphaiboon N, Guo X, Simmons A, Williamson D, Andrianova S, Berry N, Capdevila J.   +16 more
europepmc   +1 more source

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

Journal of Clinical Oncology, 2011
E. Van Cutsem, C. Köhne, I. Láng, G. Folprecht, M. Nowacki, S. Cascinu, I. Shchepotin, J. Maurel, D. Cunningham, S. Tejpar, M. Schlichting, A. Zubel, I. Celik, P. Rougier, F. Ciardiello   +14 more
semanticscholar   +1 more source

Clinical and molecular features of primary gliosarcoma with digital spatial whole‐transcriptome analysis of glial and mesenchymal components

Brain Pathology, EarlyView.
We report the clinical and genetic features of an institutional cohort of primary adult gliosarcomas compared to glioblastoma. We performed spatial whole‐transcriptome analysis on glial and sarcomatous regions of four cases to compare gene expression profiles and validated differential protein expression for two markers in tissue sections.
Matthew D. Wood, Gabriel Zangirolani, Jinho Lee, Melanie H. Hakar, Tanaya Neff, Kevin Y. Zhang, Christopher L. Corless   +6 more
wiley   +1 more source

MEK inhibition in adult patients with pilocytic astrocytomas. [PDF]

NPJ Precis Oncol
Rounis K, Delgado AF, Illies C, Shamikh A, Wangerid T, Jensdottir M, Bartek J, Persson O, Hietala MA, Friesland S, Carstens H, Stragliotto G.   +11 more
europepmc   +1 more source